Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Immunol Methods. 2014 May;407:9-14. doi: 10.1016/j.jim.2014.03.011. Epub 2014 Mar 20.

Development of a bead-based immunoassay to routinely measure vimentin autoantibodies in the clinical setting.

Author information

  • 1Department of Biochemistry, Rush University Medical Center, Chicago, IL 60612, United States.
  • 2Department of Pathology, Rush University Medical Center, Chicago, IL 60612, United States.
  • 3Department of Biochemistry, Rush University Medical Center, Chicago, IL 60612, United States; Department of Pathology, Rush University Medical Center, Chicago, IL 60612, United States. Electronic address: Jeffrey_Borgia@rush.edu.

Abstract

INTRODUCTION:

Vimentin is an intermediate filament protein generally expressed in the cytosol of many adult cell types, including leukocytes, fibroblasts and endothelial cells. Several tissue and/or injury-specific isoforms of vimentin are known to exist that may trigger autoimmune responses due to aberrant structural or conformational variations. Such scenarios include allograft rejection and certain autoimmune diseases, such as rheumatoid arthritis. The primary objective for this study was to develop a Luminex immunobead assay to quantitate circulating levels of vimentin antibodies and, secondarily, to appraise the feasibility of these autoantibodies as a biomarker for clinical diagnosis.

METHODS:

Recombinant human vimentin was conjugated to MagPlex® beads using standard carbodiimide/NHS chemistry and coupling efficiency tested and assay parameters determined using a commercial anti-vimentin polyclonal antibody. A limited number of serum samples (n=71) were then tested to evaluate the diagnostic value for future biomarker development efforts.

RESULTS:

Findings from repeated testing of three distinct batches of assays provide assay range parameters of 0.18-15μg/mL, median inter-assay recovery parameter within 1% of completion, and inter-assay variation (%CV) at 7%. The assay was found to be stable at several conditions with less than 5% loss in a month. Preliminary evaluation of the assay demonstrates significantly (p=0.022) higher circulating levels of anti-vimentin antibodies in 51 cases of renal allograft rejection relative to 20 cases of age-matched controls.

CONCLUSION:

A direct capture assay for vimentin autoantibodies was developed and analytically validated. Preliminary evaluation of this assay against patient materials was promising and justifies additional testing with larger cohorts in future studies.

Copyright © 2014 Elsevier B.V. All rights reserved.

KEYWORDS:

Analytical validation; Assay; Chronic kidney allograft rejection; Development; Luminex; Vimentin

PMID:
24657702
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk